Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
Tag: immune therapy
